Veterinary Medicines

FATROXIMIN D.C., 100mg, Intramamární mast

Authorised
  • Rifaximin
Download as PDF

Product identification

Medicine name:
FATROXIMIN D.C., 100mg, Intramamární mast
Active substance:
  • Rifaximin
Target species:
  • Cattle (dry cow)
  • Buffalo (female)
Route of administration:
  • Intramammary use

Product details

Active substance and strength:
  • Rifaximin
    100.00
    milligram(s)
    /
    1.00
    Applicator
Pharmaceutical form:
  • Intramammary ointment
Withdrawal period by route of administration:
  • Intramammary use
    • Cattle (dry cow)
      • Meat and offal
        no withdrawal period
      • Milk
        35
        day
    • Buffalo (female)
      • Meat and offal
        no withdrawal period
      • Milk
        35
        day
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QJ51XX01
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Czechia
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Fatro S.p.A.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Fatro S.p.A.
Responsible authority:
  • Institute For State Control Of Veterinary Biologicals And Medicaments
Authorisation number:
  • 96/842/97-C
Date of authorisation status change:

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Czech (PDF)
Published on: 26/10/2022
Download

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Czech (PDF)
Published on: 26/10/2022
Download

Labelling

This document does not exist in this language (English). You can find it in another language below.
Czech (PDF)
Published on: 26/10/2022
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."